Skip to main content

Table 1 Clinicopathological features of breast cancer patients studied

From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

n=96

Prior to chemotherapy

After chemotherapy

Tumour size

1,5-13 cm

0,3-14 cm

 

cT1

1 (1%)

ypT0

6 (6%)

 

-a

 

ypT1

20 (21%)

 

-b

 

-a

2

 

-c

1

-b

11

 

cT2

25 (26%)

-c

7

 

cT3

22 (23%)

ypT2

31 (32%)

 

cT4

41 (43%)

ypT3

24 (25%)

 

-b

19

ypT4

7 (7%)

 

-d

22

-b

6

 

NA

7 (7%)

-d

1

   

No surgery

8 (9%)

Lymph node status

cN0

10 (11%)

pN0

25 (26%)

 

cN1

62 (64%)

pN1

27 (28%)

 

cN2

 

pN2

12 (12%)

 

cN3

3 (3%)

pN3

14 (15%)

   

No surgery

8 (9%)

 

NA

21 (22%)

NA

10 (10%)

ER status

Positive

68 (71%)

Positive

59 (62%)

 

Negative

25 (26%)

Negative

16 (17%)

 

NA

3 (3%)

NA

21 (21%)

   

ypT0, no surgery

 

PR status

Positive

59 (62%)

Positive

46 (48%)

 

Negative

34 (35%)

Negative

29 (31%)

 

NA

3 (3%)

NA

21 (21%)

   

ypT0, no surgery

 

HER2 status

Positive

28 (29%)

Positive

18 (19%)

 

Negative

65 (68%)

Negative

57 (60%)

 

NA

3 (3%)

NA

21 (21%)

   

ypT0, no surgery

 

Ki67 status

0

2 (2%)

0

22 (28%)

 

1 (0-1%)

12 (15%)

1

21 (27%)

 

2 (1-5%)

19 (23%)

2

11 (14%)

 

3 (5-10%)

13 (16%)

3

3 (4%)

 

4 (10-15%)

6 (7%)

4

1 (1%)

 

5 (15-20%)

4 (5%)

5

6 (8%)

 

6 (20-33%)

2 (2%)

6

1 (1%)

 

7 (33-50%)

4 (5%)

7

2 (3%)

 

8 (50-66%)

1 (1%)

8

0 (0%)

 

9 (66-80%)

3 (4%)

9

3 (4%)

 

10 (80-100%)

1 (1%)

10

2 (3%)

 

NA

14 (17%)

NA

7 (9%)

 

64+17 (100%)

64+15 (100%)

  1. NA: Accurate data are not available.